Replies to post #672022 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

You can find out by doing your due diligence. I am not here to help people who undermine the company.

[sentiment_stocks]

Navid brought in Woodford’s investment money… I think that was around $180 million?

[barnstormer]

Well, Alpha, Navid has been a director for nearly 12 years. I suspect over that time he has accumulated a number of options/shares rewards. You can do the homework to look that up if you want. You might be able to use AI to do so. As to what he has done, here's his bio.

Navid Malik

Position
Independent Director
Tenure
11.8yrs
Age
54
Compensation (per year)
US$150.00k
Company Ownership
2.05 %$ 13.4m 24.2m shares
Profile
Dr. Navid Malik, Ph.D., serves as Executive Director and Head of Life Sciences Research at The Life Sciences Division Limited, Research Division. Prior to that, he served as the Head of Life Sciences Research at Cenkos Securities plc. Research Division from January 2012 to December 2015. Prior to this, Dr. Malik served as the Head of Life Sciences Equity Research at Sanlam (Merchant Securities Limited, Research Division) and Merchant Securities Group plc since September 2011 to January 2012. He was the Partner and Head of Life Sciences Research at Matrix Investment Banking Division, Matrix Group Limited from December 2008 through September 2011. Dr. Malik served as the Senior Equity Analyst at Collins Stewart plc, Research Division from January 2005 to September 2008 and also served at Williams de Broë, Research Division, covering the pharmaceutical, chemicals, healthcare and biotechnology sectors. Dr. Malik was a Senior Pharmaceuticals and Biotechnology Analyst at Wimmer Financial LLP from September 2008 to December 2008. He serves as a Director of Northwest Biotherapeutics, Inc. since April 2012. Dr. Malik has deep experience in the life sciences industry, advanced manufacturing and corporate operations and governance. He was awarded two StarMine analyst awards in 2011, ranked as the number one stock picker in the European pharmaceuticals sector and the number two stock picker in the United Kingdom and Ireland healthcare sector. Dr. Malik holds a Ph.D. in Drug Delivery within Pharmaceutical Sciences, a M.Sc. in Biomedical Sciences Research, B.Sc., joint honors in Biochemistry and Physiology. Dr. Malik holds an MBA in finance from the City University Business School, London.

[biosectinvestor]

Your knowledge is not critical to the internal decisions of the company on such matters. Some of his shares may not have been allocated your attack on this, randomly, bringing up things unrelated from 2007, when he was not a board member and involving regulatory matters, clearly you’re screaming all over the board without ANY actual information, which is bizarre. Seems like a fake effort to create noise around trying to oust a board member. And that, as I said, usually suggests interests trying to get some sort of leverage. But, in this case virtually all the points are without real information, are falsely made by implication, not facts, are extremely dated, and are literally bizarre. Strange. Not rational.